U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301814) titled 'Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors' on Dec. 11.
Brief Summary: The project aims to perform integrated PET/MR or PET/CT imaging in patients with histologically confirmed or clinically suspected gastric cancer, pancreatic cancer, cholangiocarcinoma, or other malignant tumors with high Claudin18.2 (CLDN18.2) expression, as well as healthy volunteers. This study utilizes a CLDN18.2-specific PET imaging probe (e.g., [^68Ga]Ga-labeled humanized antibody fragment) to evaluate the feasibility, accuracy, and clinical value of non-invasive, in vivo CLDN18.2 visualization.
For patients with malignant tu...